Shots:
- The US FDA has accepted sBLA of Ajovy to prevent episodic migraine in children & adolescents (6-17yrs.; ≥45Kg)
- Submission was based on P-III (SPACE) trial assessing Ajovy (SC) vs PBO for 12wks. to treat episodic migraine in 237 pediatric pts, which showed improvements in reducing monthly migraine & headache days
- Ajovy (CGRP antagonist) is available as a 225 mg/1.5 mL single-dose pre-filled syringe or pen, with 2 dosing options: 225mg (QM as 1 injection) or 675mg (Q3M as 3 injections) as SC formulation
Ref: Globenewswire | Image: Teva
Related News:- Alvotech and Teva Launch Selarsdi (Biosimilar, Stelara) in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
